DTE vs URGN
DTE (DTE) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
DTE (DTE) common stock.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
DTE does not have a complete income-statement cache yet.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
DTE currently screens at market cap $0. URGN currently screens at market cap $1.61B.
Not investment advice. Open the DTE and URGN stock pages for the full models.
Not investment advice.